DBVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DBV Technologies (DBVT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong positive catalysts, including successful Phase 3 trial results, high analyst confidence with raised price targets, and a clear regulatory path. While technical indicators are mixed, the long-term growth potential outweighs short-term volatility.
The MACD is negative and expanding, suggesting bearish momentum. RSI is neutral at 50.725, indicating no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot level of 21.976, with resistance at 23.115 and support at 20.838.
Successful Phase 3 VITESSE trial results for the VIASKIN peanut patch in children aged 4-
Analysts have raised price targets significantly, with targets ranging from $40 to $51, citing strong execution and a clear regulatory path.
Plans to submit a Biologics License Application (BLA) to the FDA in the first half of
Positive sentiment from presentations at the AAAAI 2026 Annual Meeting, highlighting the efficacy of the VIASKIN peanut patch.
The stock experienced a -3.12% drop in regular market trading, indicating short-term selling pressure.
Financial performance shows a net income loss of -33.16M in Q3 2025, although improving YoY.
In Q3 2025, revenue increased by 158.77% YoY to $2.77M, indicating strong growth. Net income improved by 8.94% YoY but remains negative at -$33.16M. EPS dropped by 25% YoY to -0.24, reflecting ongoing profitability challenges. Gross margin remains at 100%, showing efficient cost management.
Analysts are highly bullish on DBVT, with multiple firms raising price targets significantly following the positive Phase 3 VITESSE trial results. Cantor Fitzgerald, H.C. Wainwright, Citizens, and Guggenheim have all issued Buy or Overweight ratings, with price targets ranging from $40 to $51. Analysts highlight the company's strong execution, high compliance rates, and clear regulatory path as key positives.
